Many cases have been reported where EDTA is used to bind other toxic metals, forming a soluble compound that allows excretion through the urine. While not approved by the FDA, EDTA has the ability to bind other heavy metals within the body, including zinc, cadmium, mercury, and iron. The lead mobilization test allows clinicians to have a more accurate total body lead level and further guide treatment with chelation agents. Patients have a positive lead mobilization test if, in the following 24 hours, they excrete more than 6 grams of lead in their urine. The lead mobilization test is performed by administering 2 grams of EDTA through the intravenous or intramuscular route. EDTA has the ability to bind lead tightly and is more effective than other common chelators.ĮDTA is also used in a diagnostic test to assess levels of lead present within patients.
Ĭurrently, EDTA is FDA-approved for the treatment of lead poisoning in adults and children. It is commonly used in the cosmetic and food industry and has many applications within scientific laboratories. As a non-pharmacologic agent, EDTA is used in many different industries to remove toxic metal ions.
Another form, edetate disodium, has a markedly improved ability to bind calcium this form is no longer used for chelation therapy due to the high risk for hypocalcemia. As a pharmacologic agent, EDTA is used as calcium disodium edetate, which prevents it from binding calcium in the body. EDTA, which was first synthesized in the mid-1930s, has non-pharmacologic and pharmacologic purposes. This sensor can potentially be used clinically as a subcutaneously implanted continuous monitoring device in diabetic patients.Ethylenediaminetetraacetic acid (EDTA, edetate calcium disodium, calcium disodium versenate) is a chelation agent used for heavy metal toxicity. Preliminary animal testing demonstrated that the differential sensor accurately tracks glucose concentration in blood. In addition, device drift was reduced to 1.4% (uncontrolled environment) and 11% (5 ☌ of temperature variation) of that from non-differential measurements, indicating significant stability improvements. In vitro characterization demonstrated the sensor was capable of measuring glucose concentrations from 0 to 500 mg dL −1 with resolution and accuracy of ~1.7 μg dL −1 and ~1.74 mg dL −1, respectively. To accurately determine the glucose concentration, changes in the permittivity of the sensing and the reference solutions induced by changes in glucose concentration are measured differentially. The microchambers, enclosed in semi-permeable membranes, are filled with either a polymer solution that has specific affinity to glucose or a glucose-insensitive reference solution. Each module contains a microchamber housing a pair of capacitive electrodes residing on the device substrate and embedded in a suspended, perforated polymer diaphragm. The device, created using microelectromechanical systems (MEMS) technology, consists of sensing and reference modules that are identical in design and placed in close proximity. A continuous glucose monitor with a differential dielectric sensor implanted within the subcutaneous tissue that determines the glucose concentration in the interstitial fluid is presented.
0 kommentar(er)
